Skip to main content
main-content

01.12.2011 | Case report | Ausgabe 1/2011 Open Access

Journal of Medical Case Reports 1/2011

Rosiglitazone as an option for patients with acromegaly: a case series

Zeitschrift:
Journal of Medical Case Reports > Ausgabe 1/2011
Autoren:
Héctor E Tamez-Pérez, Ana Bahena-García, María D Gómez de Ossio, Hugo Gutiérrez-Hermosillo, Alejandra L Tamez-Peña
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

TH analyzed and interpreted the patient data and was a major contributor in writing the manuscript. Both BA and GM analyzed and interpreted the patient data. GH analyzed and interpreted laboratory studies. TA analyzed and interpreted the laboratory studies and the statistical reporting. All authors read and approved the final manuscript.

Abstract

Introduction

In the patient with acromegaly, pituitary surgery is the therapeutic standard. Despite undergoing surgery, a significant number of patients with acromegaly continue to have uncontrolled growth hormone secretion. These patients require other treatments such as external irradiation and/or drug therapy.

Case presentation

We present the clinical and laboratory responses to six months of treatment with rosiglitazone in four cases. In all four cases, the patients had persistent growth hormone overproduction despite previous surgical treatment and other conventional therapy. Case 1 is a 57-year-old Caucasian woman, case 2 is a 51-year-old Hispanic man, case 3 is a 32-year-old Hispanic woman, and case 4 is a 36-year-old Hispanic man. In three of these patients, basal and nadir growth hormone and insulin-like growth factor 1 levels were significantly decreased (P < 0.05 and P < 0.01, respectively).

Conclusion

Rosiglitazone could be a treatment option in select patients with acromegaly.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

e.Med Allgemeinmedizin

Kombi-Abonnement

Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2011

Journal of Medical Case Reports 1/2011 Zur Ausgabe